ADGRG3

Summary

ADGRG3 (adhesion G protein-coupled receptor G3, HGNC:13728) is a protein-coding gene on chromosome 16q21, encoding Adhesion G protein-coupled receptor G3 (Q86Y34). Adhesion G-protein coupled receptor (aGPCR) for glucocorticoid hormones such as cortisol, cortisone and 11-deoxycortisol.

Predicted to enable G protein-coupled receptor activity. Involved in G protein-coupled receptor signaling pathway and regulation of cell migration. Located in plasma membrane.

Source: NCBI Gene 222487 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 112 total
• Druggable target: yes
• MANE Select transcript: NM_170776

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13728
Approved symbol	ADGRG3
Name	adhesion G protein-coupled receptor G3
Location	16q21
Locus type	gene with protein product
Status	Approved
Aliases	Pb99, PGR26
Ensembl gene	ENSG00000182885
Ensembl biotype	protein_coding
OMIM	618441
Entrez	222487

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 4 protein_coding, 3 retained_intron, 2 nonsense_mediated_decay

ENST00000333493, ENST00000450388, ENST00000565579, ENST00000565902, ENST00000567991, ENST00000568245, ENST00000569977, ENST00000858859, ENST00000945139

RefSeq mRNA: 2 — MANE Select: NM_170776 NM_001308360, NM_170776

CCDS: CCDS10786, CCDS76879

Canonical transcript exons

ENST00000333493 — 12 exons

Exon	Start	End
ENSE00001299310	57683932	57684212
ENSE00002604333	57668306	57668405
ENSE00003458754	57680505	57680617
ENSE00003484022	57678170	57678316
ENSE00003501715	57679177	57679311
ENSE00003517920	57676200	57676338
ENSE00003571340	57688352	57689378
ENSE00003574256	57673321	57673468
ENSE00003607091	57679816	57679855
ENSE00003627682	57680265	57680365
ENSE00003639584	57685643	57685926
ENSE00003666883	57684390	57684483

Expression profiles

Bgee: expression breadth ubiquitous, 163 present calls, max score 94.77.

FANTOM5 (CAGE): breadth broad, TPM avg 10.9430 / max 3584.3714, expressed in 233 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
154415	7.4685	199
154414	3.4324	139
207901	0.0421	7

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	94.77	gold quality
spleen	UBERON:0002106	89.39	gold quality
granulocyte	CL:0000094	88.51	gold quality
bone marrow	UBERON:0002371	88.06	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.33	silver quality
right lung	UBERON:0002167	86.07	gold quality
bone marrow cell	CL:0002092	85.94	gold quality
upper lobe of left lung	UBERON:0008952	84.89	gold quality
upper lobe of lung	UBERON:0008948	82.48	gold quality
left uterine tube	UBERON:0001303	80.10	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	79.95	gold quality
periodontal ligament	UBERON:0008266	79.76	gold quality
omental fat pad	UBERON:0010414	78.77	gold quality
peritoneum	UBERON:0002358	78.67	gold quality
vermiform appendix	UBERON:0001154	78.29	gold quality
trabecular bone tissue	UBERON:0002483	78.20	gold quality
lower esophagus mucosa	UBERON:0035834	77.91	gold quality
adipose tissue of abdominal region	UBERON:0007808	77.64	gold quality
left lobe of thyroid gland	UBERON:0001120	75.86	gold quality
right lobe of thyroid gland	UBERON:0001119	74.96	gold quality
leukocyte	CL:0000738	74.07	gold quality
thyroid gland	UBERON:0002046	73.89	gold quality
small intestine Peyer’s patch	UBERON:0003454	73.62	gold quality
monocyte	CL:0000576	72.79	gold quality
caecum	UBERON:0001153	72.79	gold quality
mononuclear cell	CL:0000842	72.72	gold quality
small intestine	UBERON:0002108	71.51	gold quality
gall bladder	UBERON:0002110	70.67	gold quality
right lobe of liver	UBERON:0001114	69.92	gold quality
lower esophagus	UBERON:0013473	69.37	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-6678	yes	32.51
E-MTAB-9801	yes	8.23
E-ANND-3	yes	8.15

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NFKB1, RELA

miRNA regulators (miRDB)

28 targeting ADGRG3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-432-3P	100.00	67.86	705
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-MIR-4492	99.87	68.25	3611
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-7156-5P	99.64	68.81	1369
HSA-MIR-6861-3P	99.60	68.46	444
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-203A-3P	99.49	70.56	2806
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-4273	99.45	67.93	1206
HSA-MIR-4721	99.26	66.05	818
HSA-MIR-5001-5P	99.05	66.76	1972
HSA-MIR-760	98.81	66.65	1392
HSA-MIR-2117	98.48	67.97	1307
HSA-MIR-3664-3P	97.85	67.62	1452
HSA-MIR-3652	97.71	65.43	1890
HSA-MIR-4430	97.47	65.61	1813
HSA-MIR-4786-5P	97.45	67.89	924
HSA-MIR-1225-3P	97.29	64.60	876
HSA-MIR-4535	97.27	65.17	469
HSA-MIR-4776-5P	97.14	66.63	405
HSA-MIR-4749-3P	96.40	66.24	798
HSA-MIR-9900	96.06	65.48	557

Literature-anchored findings (GeneRIF, showing 5)

• a possible role of GPR97 in lymphatic remodeling (PMID:24178298)
• Ligation of GPR97 increased the bacteria uptake. (PMID:30559745)
• Structures of the glucocorticoid-bound adhesion receptor GPR97-Go complex. (PMID:33408414)
• Curcumin activates G protein-coupled receptor 97 (GPR97) in a manner different from glucocorticoid. (PMID:35093639)
• GPR97 triggers inflammatory processes in human neutrophils via a macromolecular complex upstream of PAR2 activation. (PMID:36302784)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	adgrg1	ENSDARG00000027222
danio_rerio		ENSDARG00000110748
danio_rerio		ENSDARG00000114465
mus_musculus	Adgrg3	ENSMUSG00000060470
rattus_norvegicus	Adgrg3	ENSRNOG00000014896

Paralogs (42): CALCR (ENSG00000004948), GIPR (ENSG00000010310), ADGRA2 (ENSG00000020181), CALCRL (ENSG00000064989), GLP2R (ENSG00000065325), ADGRF5 (ENSG00000069122), ADGRL1 (ENSG00000072071), ADCYAP1R1 (ENSG00000078549), SCTR (ENSG00000080293), VIPR2 (ENSG00000106018), CRHR2 (ENSG00000106113), GHRHR (ENSG00000106128), ADGRD1 (ENSG00000111452), GLP1R (ENSG00000112164), ADGRG6 (ENSG00000112414), VIPR1 (ENSG00000114812), ADGRL2 (ENSG00000117114), CRHR1 (ENSG00000120088), ADGRB2 (ENSG00000121753), ADGRE5 (ENSG00000123146), ADGRE2 (ENSG00000127507), ADGRE3 (ENSG00000131355), ADGRB3 (ENSG00000135298), PTH2R (ENSG00000144407), ADGRG7 (ENSG00000144820), ADGRL3 (ENSG00000150471), ADGRA3 (ENSG00000152990), ADGRF1 (ENSG00000153292), ADGRF4 (ENSG00000153294), ADGRG4 (ENSG00000156920), ADGRG5 (ENSG00000159618), PTH1R (ENSG00000160801), ADGRL4 (ENSG00000162618), EVA1C (ENSG00000166979), ADGRF3 (ENSG00000173567), ADGRG2 (ENSG00000173698), ADGRE1 (ENSG00000174837), ADGRD2 (ENSG00000180264), ADGRB1 (ENSG00000181790), ADGRA1 (ENSG00000197177)

Protein

Protein identifiers

Adhesion G protein-coupled receptor G3 — Q86Y34 (reviewed: Q86Y34)

Alternative names: G-protein coupled receptor 97

All UniProt accessions (4): Q86Y34, F8W8F7, H3BRU4, H3BS78

UniProt curated annotations — full annotation on UniProt →

Function. Adhesion G-protein coupled receptor (aGPCR) for glucocorticoid hormones such as cortisol, cortisone and 11-deoxycortisol. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. ADGRG3/GPR97 is coupled to G(o)/GNAO1 G proteins and mediates signaling by inhibiting adenylate cyclase activity. May also signal through G-alpha(q)-proteins; additional evidence are however required to confirm this result in vivo. Plays a role in the regulation of various processes including B-cell development, inflammation or innate immunity. Regulates migration of lymphatic endothelial cells in vitro via the small GTPases RhoA and CDC42. Antibody ligation leads to the production and activation of antimicrobial mediators like reactive oxygen species (ROS) and myeloperoxidase (MPO) as well as enhanced bacteria uptake and killing by granulocytes. Additionally, collaborates with protease-activated receptor 2/PAR2 to stimulate neutrophil-driven antimicrobial responses and endothelial cell activation.

Subunit / interactions. Heterodimer of 2 chains generated by proteolytic processing; the large extracellular N-terminal fragment and the membrane-bound C-terminal fragment predominantly remain associated and non-covalently linked. Interacts with PRTN3; this interaction induces the activation of PAR2. Interacts with GNAO1 (when palmitoylated).

Subcellular location. Cell membrane.

Tissue specificity. Expressed in cultured primary dermal lymphatic endothelial cells. Highly expressed in polymorphonuclear cells (PMNs) including neutrophilic, eosinophilic, and basophilic granulocytes.

Post-translational modifications. Autoproteolytically processed at the GPS region of the GAIN-B domain; this cleavage modulates receptor activity. O- and N-glycosylated.

Activity regulation. Forms a heterodimer of 2 chains generated by proteolytic processing that remain associated through non-covalent interactions mediated by the GAIN-B domain. In the inactivated receptor, the Stachel sequence (also named stalk) is embedded in the GAIN-B domain, where it adopts a beta-strand conformation. On activation, the Stachel moves into the 7 transmembrane region and adopts a twisted hook-shaped configuration that forms contacts within the receptor, leading to coupling of a G-alpha protein, which activates signaling. The cleaved GAIN-B and N-terminal domains can then dissociate from the rest of the receptor.

Domain organisation. The Stachel sequence (also named stalk) in the C-terminal part of the extracellular domain (ECD) functions as a tethered agonist. In the inactivated receptor, the Stachel sequence (also named stalk) is embedded in the GAIN-B domain, where it adopts a beta-strand conformation. On activation, the Stachel moves into the 7 transmembrane region and adopts a twisted hook-shaped configuration that forms contacts within the receptor, leading to coupling of a G-alpha protein, which activates signaling.

Induction. Under inflammatory conditions.

Similarity. Belongs to the G-protein coupled receptor 2 family. Adhesion G-protein coupled receptor (ADGR) subfamily.

RefSeq proteins (2): NP_001295289, NP_740746* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000203	GPS	Conserved_site
IPR000832	GPCR_2_secretin-like	Family
IPR003910	GPR1/GPR3/GPR5	Family
IPR017981	GPCR_2-like_7TM	Domain
IPR046338	GAIN_dom_sf	Homologous_superfamily
IPR057244	GAIN_B	Domain

Pfam: PF00002, PF01825

UniProt features (73 total): strand 17, helix 15, topological domain 8, transmembrane region 7, sequence conflict 5, glycosylation site 4, turn 4, chain 3, disulfide bond 3, region of interest 2, signal peptide 1, domain 1, binding site 1, site 1, sequence variant 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
7D77	ELECTRON MICROSCOPY	2.9
7D76	ELECTRON MICROSCOPY	3.1
7QU8	X-RAY DIFFRACTION	3.37

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86Y34-F1	80.48	0.40

Antibody-complex structures (SAbDab): 1 — 7D77

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 249–250 (cleavage; by autolysis)

Ligand- & substrate-binding residues (1): 510

Disulfide bonds (3): 215–244, 233–246, 338–420

Glycosylation sites (4): 98, 144, 210, 413

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-6798695	Neutrophil degranulation
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System

MSigDB gene sets: 202 (showing top): GSE45365_NK_CELL_VS_BCELL_DN, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_B_CELL_ACTIVATION, GOCC_SECRETORY_GRANULE, CEBPB_01, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_ADENYLATE_CYCLASE_MODULATING_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_REGULATION_OF_NON_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GOBP_NON_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, MORI_PRE_BI_LYMPHOCYTE_UP, PU1_Q6, chr16q21, RYTTCCTG_ETS2_B, VDR_Q3

GO Biological Process (8): cell surface receptor signaling pathway (GO:0007166), G protein-coupled receptor signaling pathway (GO:0007186), adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway (GO:0007193), B cell differentiation (GO:0030183), regulation of cell migration (GO:0030334), obsolete negative regulation of CREB transcription factor activity (GO:0032792), negative regulation of non-canonical NF-kappaB signal transduction (GO:1901223), signal transduction (GO:0007165)

GO Molecular Function (3): G protein-coupled receptor activity (GO:0004930), transmembrane signaling receptor activity (GO:0004888), protein binding (GO:0005515)

GO Cellular Component (3): plasma membrane (GO:0005886), membrane (GO:0016020), specific granule membrane (GO:0035579)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Innate Immune System	1
Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
signal transduction	2
G protein-coupled receptor activity	1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
adenylate cyclase inhibitor activity	1
lymphocyte differentiation	1
B cell activation	1
cell migration	1
regulation of cell motility	1
non-canonical NF-kappaB signal transduction	1
regulation of non-canonical NF-kappaB signal transduction	1
negative regulation of intracellular signal transduction	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
transmembrane signaling receptor activity	1
G protein-coupled receptor signaling pathway	1
signaling receptor activity	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1
secretory granule membrane	1
specific granule	1

Protein interactions and networks

STRING

630 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ADGRG3	GNAO1	P09471	676
ADGRG3	ADGRA1	Q86SQ6	612
ADGRG3	ADGRA3	Q8IWK6	551
ADGRG3	ADGRG5	Q8IZF4	378
ADGRG3	PSMD5	Q16401	348
ADGRG3	ADGRA2	Q96PE1	345
ADGRG3	ADGRF5	Q8IZF2	331
ADGRG3	ADGRF2P	Q8IZF7	318
ADGRG3	ADGRG4	Q8IZF6	307
ADGRG3	MCEMP1	Q8IX19	304
ADGRG3	MCTP2	Q6DN12	301
ADGRG3	ADGRV1	Q8WXG9	301
ADGRG3	ADGRL1	O94910	291
ADGRG3	ADGRF1	Q5T601	287
ADGRG3	ADGRF4	Q8IZF3	278

IntAct

38 interactions, top by confidence:

A	B	Type	Score
LHFPL5	ADGRG3	psi-mi:“MI:0915”(physical association)	0.560
SEC22A	ADGRG3	psi-mi:“MI:0915”(physical association)	0.560
ADGRG3	ATP6V0B	psi-mi:“MI:0915”(physical association)	0.560
ADGRG3	ARLN	psi-mi:“MI:0915”(physical association)	0.560
ADGRG3	TEX264	psi-mi:“MI:0915”(physical association)	0.560
VSTM1	ADGRG3	psi-mi:“MI:0915”(physical association)	0.560
UPK2	ADGRG3	psi-mi:“MI:0915”(physical association)	0.560
TTMP	ADGRG3	psi-mi:“MI:0915”(physical association)	0.560
ADGRG3	LHFPL5	psi-mi:“MI:0915”(physical association)	0.560
ADGRG3	GIMAP5	psi-mi:“MI:0915”(physical association)	0.560
PLP1	ADGRG3	psi-mi:“MI:0915”(physical association)	0.560
ADGRG3	RPRM	psi-mi:“MI:0915”(physical association)	0.560
CTXN3	ADGRG3	psi-mi:“MI:0915”(physical association)	0.560
ADGRG3	SEC22A	psi-mi:“MI:0915”(physical association)	0.560
HRAS	IGKV2D-24	psi-mi:“MI:0914”(association)	0.350
ARLN	ADGRG3	psi-mi:“MI:0915”(physical association)	0.000
TEX264	ADGRG3	psi-mi:“MI:0915”(physical association)	0.000
VSTM1	ADGRG3	psi-mi:“MI:0915”(physical association)	0.000
UPK2	ADGRG3	psi-mi:“MI:0915”(physical association)	0.000
GIMAP5	ADGRG3	psi-mi:“MI:0915”(physical association)	0.000
PLP1	ADGRG3	psi-mi:“MI:0915”(physical association)	0.000
RPRM	ADGRG3	psi-mi:“MI:0915”(physical association)	0.000
CTXN3	ADGRG3	psi-mi:“MI:0915”(physical association)	0.000
ATP6V0B	ADGRG3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (13): GPR97 (Two-hybrid), GPR97 (Two-hybrid), GPR97 (Two-hybrid), GPR97 (Two-hybrid), GPR97 (Two-hybrid), GPR97 (Two-hybrid), GPR97 (Two-hybrid), GPR97 (Two-hybrid), VSTM1 (Two-hybrid), GIMAP5 (Two-hybrid), LHFPL5 (Two-hybrid), CTXN3 (Two-hybrid), GPR97 (Proximity Label-MS)

ESM2 similar proteins: E7FBY6, O35674, O43184, P11688, P21463, P47750, P48960, P56495, Q06418, Q14246, Q27987, Q2Q421, Q2Q426, Q3V3Z3, Q49HI0, Q50DM5, Q50DM6, Q50DM7, Q50DM8, Q5SZV5, Q5Y4N8, Q61549, Q61824, Q6F3F9, Q7RTX1, Q7Z443, Q86Y34, Q8CJ11, Q8CJ12, Q8IZF5, Q8IZP9, Q8K209, Q8K3V3, Q8R0T6, Q8SPP9, Q8SQA4, Q90674, Q91ZE5, Q91ZV8, Q923K1

Diamond homologs: B7ZCC9, C6KFA3, G5ECX0, G5EDW2, O88917, O94910, O97817, O97827, O97831, Q2Q421, Q2Q426, Q3V3Z3, Q50DM5, Q50DM6, Q50DM7, Q50DM8, Q6F3F9, Q6QNK2, Q7SY09, Q80TR1, Q80TS3, Q86SQ3, Q86SQ4, Q86Y34, Q8CJ11, Q8CJ12, Q8IZF4, Q8IZF6, Q8IZP9, Q8JZZ7, Q8K209, Q8SQA4, Q923X1, Q9BY15, Q9ESC1, Q9HAR2, Q9HBW9, Q9HCU4, Q9QYP2, Q9R0M0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

112 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	90
Likely benign	13
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2147 predictions. Top by Δscore:

Variant	Effect	Δscore
16:57673316:CTTA:C	acceptor_loss	1.0000
16:57673317:TTA:T	acceptor_loss	1.0000
16:57673318:TA:T	acceptor_loss	1.0000
16:57673319:A:AC	acceptor_loss	1.0000
16:57673319:A:AG	acceptor_gain	1.0000
16:57673320:G:GG	acceptor_gain	1.0000
16:57673320:GGTCA:G	acceptor_gain	1.0000
16:57673466:GAG:G	donor_gain	1.0000
16:57673468:GGT:G	donor_loss	1.0000
16:57673469:G:GA	donor_loss	1.0000
16:57673470:T:G	donor_loss	1.0000
16:57676334:CTCAG:C	donor_loss	1.0000
16:57676335:TCAGG:T	donor_loss	1.0000
16:57676336:CAGGT:C	donor_loss	1.0000
16:57676337:AG:A	donor_loss	1.0000
16:57676338:GG:G	donor_loss	1.0000
16:57676339:GT:G	donor_loss	1.0000
16:57678314:AAG:A	donor_loss	1.0000
16:57678317:G:GA	donor_loss	1.0000
16:57678318:T:G	donor_loss	1.0000
16:57679175:AG:A	acceptor_gain	1.0000
16:57679176:GG:G	acceptor_gain	1.0000
16:57679312:G:GG	donor_gain	1.0000
16:57680503:A:AG	acceptor_gain	1.0000
16:57680504:G:GG	acceptor_gain	1.0000
16:57680616:AGGTG:A	donor_loss	1.0000
16:57680617:GGT:G	donor_loss	1.0000
16:57680618:GT:G	donor_loss	1.0000
16:57680619:T:A	donor_loss	1.0000
16:57684479:GAGCT:G	donor_gain	1.0000

AlphaMissense

3562 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:57680281:G:C	W228C	0.992
16:57680281:G:T	W228C	0.992
16:57679837:T:C	F217L	0.990
16:57679839:C:A	F217L	0.990
16:57679839:C:G	F217L	0.990
16:57679842:G:C	W218C	0.990
16:57679842:G:T	W218C	0.990
16:57683993:A:C	S315R	0.987
16:57683995:C:A	S315R	0.987
16:57683995:C:G	S315R	0.987
16:57680351:T:C	F252L	0.982
16:57680353:C:A	F252L	0.982
16:57680353:C:G	F252L	0.982
16:57680279:T:A	W228R	0.981
16:57680279:T:C	W228R	0.981
16:57684209:T:A	W387R	0.980
16:57684209:T:C	W387R	0.980
16:57685926:G:C	G514R	0.979
16:57685854:T:A	W490R	0.978
16:57685854:T:C	W490R	0.978
16:57679832:G:A	C215Y	0.973
16:57684017:T:C	F323L	0.973
16:57684019:C:A	F323L	0.973
16:57684019:C:G	F323L	0.973
16:57680352:T:G	F252C	0.972
16:57685902:T:C	F506L	0.970
16:57685904:T:A	F506L	0.970
16:57685904:T:G	F506L	0.970
16:57679289:T:G	F202C	0.969
16:57684113:T:A	W355R	0.969

dbSNP variants (sampled 300 via entrez): RS1000099356 (16:57672037 A>G), RS1000122903 (16:57664604 T>C), RS1000153912 (16:57664396 C>G,T), RS1000320039 (16:57669729 C>A,T), RS1000691433 (16:57685880 G>A), RS1001373925 (16:57664064 G>A), RS1001533262 (16:57674830 A>C), RS1001647753 (16:57674611 C>A), RS1001678744 (16:57674382 C>T), RS1001804175 (16:57680215 C>A,T), RS1001941228 (16:57685365 T>C), RS1001967300 (16:57685039 G>A), RS1002345429 (16:57665584 T>C), RS1002377907 (16:57665310 T>C), RS1002640119 (16:57682710 C>T)

Disease associations

OMIM: gene MIM:618441 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3559707 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Adhesion Class GPCRs

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
beclometasone dipropionate	Full agonist	8.5	pEC50

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
GSK-J4	decreases expression	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
sulforaphane	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
perfluorooctanoic acid	decreases expression	1
cupric chloride	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
abrine	increases expression	1
licochalcone B	decreases expression	1
bisphenol S	decreases expression	1
Leflunomide	increases expression	1
Acetaminophen	decreases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Tobacco Smoke Pollution	affects expression	1
Tretinoin	increases expression	1
Urethane	decreases expression	1
Cyclosporine	increases expression	1
Okadaic Acid	increases expression	1
Particulate Matter	increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4883475	Binding	PRESTO-Tango GPCRome screening (GPR97)	Data for DCP probe UCSF924

Cellosaurus cell lines

1 cell lines: 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_KX79	PathHunter CHO-K1 GPR97 beta-arrestin	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.